Economic evaluation of sorafenib in unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

Published:2010-06-07 Issue:11 Volume:25 Page:1739-1746
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:

Author:

Carr Brian I.,Carroll Stuart,Muszbek Noemi,Gondek Kathleen

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1746.2010.06404.x/fullpdf

Reference33 articles.

1. Updated treatment approach to hepatocellular carcinoma;Llovet;J. Gastroenterol.,2005

2. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme);Cancer of the Liver Group;Lancet,1998

3. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial;Lai;Hepatology,1993

4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival;Llovet;Hepatology,2003

5. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation;Perry;Liver Int.,2007

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review;Health Economics Review;2024-07-05

2. Cost-effectiveness analysis: The missing factor in the management of HCC;Clinical Liver Disease;2024-01

3. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma;PLOS ONE;2023-10-05

4. ANALYSIS OF SIGNAL TRANSDUCTION PATHWAYS THAT MEDIATE RESISTANCE OF LIVER CANCER STEM CELLS TO SORAFENIB;ACTA MEDICA MEDITERR;2023

5. Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis;Cancer;2022-09-16